A recent study showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients who ultimately take the drugs, raising questions about the direct applicability of trial data.
Scientists used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial.
Clinical Trial Demonstrates Safety of Immunotherapy Drug Combinations in Small Cell and Non-Small Cell Lung CancersSeptember 28, 2015
Pembrolizumab, an immunotherapy drug that unmasks cancer cells allowing the body's immune system to destroy tumors, appears to be safe in treating lung cancers, according to a study presented at the 16th World Conference on Lung Cancer.
Eight of 14 patients in the first clinical trial of personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing beyond 4.5 years.
Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
A new technique has been developed by statisticians to help doctors optimize dosing new cancer treatments in phase I/II clinical trials.
A genetically engineered herpes virus can be used to kill off skin cancer cells and galvanize the immune system, according to phase 3 clinical trial data.
Clinical trial results showed good performance employing the investigational drug brigatinib against ALK-positive non-small cell lung cancer (NSCLC).
Drugs that are more commonly used to treat melanoma can also be use to help some individuals with lung cancer, research indicates.
[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.
Personalized melanoma vaccines can be used to galvanize a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial.
Adrenal cancer is among the more rare and aggressive forms of cancer, but new research indicates the possibility of personalized treatment.
A subset of adrenal cancer patients responded well to drug treatment in a phase 3 trial, giving some hope for addressing this aggressive form of cancer.
A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.
New evidence indicates that combining chemotherapy with radiation therapy may be the best option for people with a low-grade form of brain cancer.
A previous history of cancer cancer did not impact clinical outcomes in advanced lung cancer patients and these patients therefore should be considered for inclusion in clinical trials, according to a study .
The antibody MPDL3280A, which blocks the protein PD-L1, resulted in tumor shrinkage in slightly over half of tested patients with advanced bladder cancer.
Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.
The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.
Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.
A new drug that targets common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), and a type of the mutation responsible for treatment resistance, has shown promising results in a phase I/II clinical trial.
The first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1 has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation.
The anticancer drug galeterone has proved successful in lowering prostate-specific antigen levels in men with castration-resistant prostate cancer (CRPC).
A method to determine which patients with ovarian cancer are more likely to respond well to the new anticancer drug rucaparib has been discovered.
Previously, patients with advanced colorectal cancer driven by a mutated version of the BRAF gene have had limited treatment options, but results from a multicenter clinical trial suggest a new option.
Patients with B-cell non-Hodgkin lymphomas and advanced solid tumors have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.
Latina patients with breast cancer had much more awareness of clinical trials versus women who received the typical information.
An investigational personalized cellular therapy was found to have achieved remission in some 90% of children and adults with acute lymphoblastic leukemia (ALL) tested.
A new drug breakthrough could extend the life of people living with glioblastoma, the most aggressive type of brain cancer.
A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.
- Harms of Cigarette Smoking and Health Benefits of Quitting (Fact Sheet)
- Clinical Trial Shows Vaccine Clears Some Precancerous Cervical Lesions
- Late-Stage Lung Cancer Often Overtreated
- Biomarker May Predict Prognosis for Targeted Therapy in Patients With HER2-Negative Breast Cancer
- "Supportive care" may hold less stigma than "palliative care"
- Engineered Switch in Immune Cell Technology Makes Therapy More Precise, and Safer
- Testosterone Therapy Does Not Increase Aggressive Prostate Cancer Risk
- Laparascopic Surgery Does Not Improve Outcomes Over Open Resection for Rectal Cancer
- Bisphosphonates May Be Useful as Palliative Measure in Selected Patients
- Smokers and Nonsmokers Who Develop NSCLC Display Differences
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|